Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Show all 393 references

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 201–300 of 998

The Pharmacology of Visual Hallucinations in Synucleinopathies
Russo, M., Carrarini, C., Dono, F., Rispoli, M. G., Pietro, M. D., Stefano, V. D., Ferri, L., Bonanni, L., Sensi, S. L., & ONOFRJ, M. C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01379 · Cited by 58
A proteomic approach to receptor signaling: Molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex
Kabbani, N., & Levenson, R. G. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.059 · Cited by 54
Alexithymia and regional gray matter alterations in schizophrenia
Kubota, M., Miyata, J., Hirao, K., Fujiwara, H., Kawada, R., Fujimoto, S., Tanaka, Y. Z., Sasamoto, A., Sawamoto, N., Fukuyama, H., et al. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.01.019 · Cited by 53
Phosphodiesterase 10A Regulates Alcohol and Saccharin Self-Administration in Rats
Logrip, M. L., Vendruscolo, L. F., Schlosburg, J. E., Koob, G. F., & Zorrilla, E. P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.20 · Cited by 53
Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies
Panariello, F., Luca, V. D., & de Bartolomeis, A. (2010) · Schizophrenia Research and Treatment · doi:10.1155/2011/459284 · Cited by 53
Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine
Santarelli, D. M., Liu, B., Duncan, C. E., Beveridge, N. J., Tooney, P. A., Schofield, P. R., & Cairns, M. J. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2939-y · Cited by 52
Neurobiological Determinants of Tobacco Smoking in Schizophrenia
Lucatch, A. M., Lowe, D. J. E., Clark, R. C., Kozak, K., & George, T. P. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00672 · Cited by 54
Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era
Marino, M. J., Knutsen, L. J. S., & Williams, M. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701094q · Cited by 52
Quetiapine attenuates the depressive and anxiolytic-like behavioural changes induced by global cerebral ischemia in mice
Yan, B., He, J., Xu, H., Zhang, Y., Bi, X., THAKUR, S., Gendron, A., Kong, J., & LI, X. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.05.002 · Cited by 52
Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability
Linton, D., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0355-6 · Cited by 52
Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication
Greenbaum, L., Strous, R. D., Kanyas, K., Merbl, Y., Horowitz, A., Karni, O., Katz, E., Kotler, M., Olender, T., Deshpande, S. N., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32800ffbb4 · Cited by 51
Association Study of Tryptophan Hydroxylase-2 Gene in Schizophrenia and Its Clinical Features in Chinese Han Population
Zhang, C., Li, Z., Shao, Y., Xie, B., Du, Y., Fang, Y., & Yu, S. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9458-2 · Cited by 51
The Promise and Reality of Pharmacogenetics in Psychiatry
Zandi, P. P., & Judy, J. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.001 · Cited by 50
Antipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanisms
Li, M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116654697 · Cited by 51
mRNA Expression and DNA Methylation Analysis of Serotonin Receptor 2A (HTR2A) in the Human Schizophrenic Brain
Cheah, S.-Y., Lawford, B., Young, R., Morris, C., & Voisey, J. (2017) · Genes · doi:10.3390/genes8010014 · Cited by 50
Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model
Haaf, M., Leicht, G., Ćurić, S., & Mulert, C. (2018) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201019666180620112528 · Cited by 52
Haloperidol Disrupts Lipid Rafts and Impairs Insulin Signaling in SH-SY5Y Cells
Sánchez-Wandelmer, J., Dávalos, A., de la Peña, G., Cano, S., Giera, M., Canfrán-Duque, A., Bracher, F., Martín-Hidalgo, A., Fernández-Hernando, C., Lasunción, M. A., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.051 · Cited by 49
Association of Gestational Weight Gain and Maternal Body Mass Index in Early Pregnancy With Risk for Nonaffective Psychosis in Offspring
MacKay, E. N., Dalman, C., Karlsson, H., & Gardner, R. M. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.4257 · Cited by 51
Repurposing Antipsychotics for Cancer Treatment
Vlachos, N., Lampros, M. G., Voulgaris, S., & Alexiou, G. Α. (2021) · Biomedicines · doi:10.3390/biomedicines9121785 · Cited by 51
Regulation of macrophage immune responses by antipsychotic drugs
Chen, M., Wu, S., Tsai, T., Wang, L., & Tsai, F. (2013) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2013.828744 · Cited by 50
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Pogorelov, V. M., Rodriguiz, R. M., Cheng, J., Huang, M., Schmerberg, C. M., Meltzer, H. Y., Roth, B. L., Kozikowski, A. P., & Wetsel, W. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.52 · Cited by 52
N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats
Möller, M., du Preez, J. L., Viljoen, F. P., Berk, M., & Harvey, B. H. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9433-z · Cited by 48
History, background, concepts and current use of comedication and polypharmacy in psychiatry
Möller, H. ‐., Seemüller, F., Schennach-Wolff, R., Stübner, S., Rüther, E., & Grohmann, R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000837 · Cited by 52
Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics
Moschny, N., Hefner, G., Grohmann, R., Eckermann, G., Maier, H. B., Seifert, J., Heck, J., Francis, F., Bleich, S., Toto, S., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14060514 · Cited by 53
Role of glutamate in schizophrenia: integrating excitatory avenues of research
Sodhi, M., Wood, K. H., & Meador‐Woodruff, J. H. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.9.1389 · Cited by 49
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol
KRAKOWSKI, M. I., Tural, Ü., & Czobor, P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010052 · Cited by 51
Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics
Lafuente, A., Bernardo, M., Mas, S., Crescenti, A., Aparici, M., Gassó, P., Catalán, R., Mateos, J. J., Lomeña, F., & Parellada, E. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.031 · Cited by 48
Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Terry, A. V. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777247 · Cited by 48
Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations
Walss‐Bass, C., Weintraub, S. T., Hatch, J. P., Mintz, J., & Chaudhuri, A. R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008882 · Cited by 48
Regulation of membrane NMDA receptors by dynamics and protein interactions
Petit‐Pedrol, M., & Groc, L. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.202006101 · Cited by 46
Critical appraisal of lurasidone in the management of schizophrenia
Caccia, S., Pasina, L., & Nobili, A. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s18059 · Cited by 47
Synthesis and biological activities of indolizine derivatives as alpha-7 nAChR agonists
Xue, Y., Tang, J., Ma, X., Li, Q., Xie, B., Hao, Y., Jin, H., Wang, K., Zhang, G., Zhang, L., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.016 · Cited by 47
Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials
Lao, K. S. J., He, Y., Wong, I. C. K., Besag, F., & Chan, E. W. (2016) · CNS Drugs · doi:10.1007/s40263-016-0382-z · Cited by 47
A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice
Motyl, K. J., Beauchemin, M., Barlow, D. J., Le, P. T., Nagano, K., Treyball, A., Contractor, A., Baron, R., Rosen, C. J., & Houseknecht, K. L. (2017) · Bone · doi:10.1016/j.bone.2017.07.008 · Cited by 47
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
Torrisi, S. A., Laudani, S., Contarini, G., Luca, A. D., Geraci, F., Managò, F., Papaleo, F., Salomone, S., Drago, F., & Leggio, G. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110365 · Cited by 50
Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3′-untranslated region
Greenbaum, L., Smith, R. C., Rigbi, A., Strous, R. D., Teltsh, O., Kanyas, K., Korner, M., Lancet, D., Ben‐Asher, E., & Lerer, B. (2008) · The Pharmacogenomics Journal · doi:10.1038/tpj.2008.6 · Cited by 47
An association study of DRD2 gene polymorphisms with schizophrenia in a Chinese Han population
Fan, H., Zhang, F., Xu, Y. J., Huang, X., Sun, G., Song, Y., Long, H., & Liu, P. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.017 · Cited by 46
Differential Repression by Freud-1/CC2D1A at a Polymorphic Site in the Dopamine-D2 Receptor Gene
Rogaeva, A., Ou, X., Jafar‐Nejad, H., Lemonde, S., & Albert, P. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610038200 · Cited by 45
Effects of fluoxetine on ethanol withdrawal syndrome in rats
Uzbay, T. I., lam, E. S., Kayır, H., Çelik, T., & Beyazyürek, M. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.11.007 · Cited by 47
Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome
Barak, S. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.04.006 · Cited by 50
Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins
Kurosawa, S., Hashimoto, E., Ukai, W., Toki, S., Saitô, S., & Saito, T. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0747-z · Cited by 46
Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients
Genetic Risk and Outcome in Psychosis (GROUP) investigators, Koning, J., Vehof, J., Burger, H., Wilffert, B., Hadithy, A. A., Alizadeh, B. Z., van Harten, P. N., & Snieder, H. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2394-1 · Cited by 46
Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice
Mutlu, O., Ulak, G., Celikyurt, I. K., Akar, F., & Erden, F. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.009 · Cited by 46
Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism
Aringhieri, S., Kolachalam, S., Gerace, C., Carli, M., Verdesca, V., Brunacci, M. G., Rossi, C., Ippolito, C., Solini, A., Corsini, G. U., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.005 · Cited by 46
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Amato, D., Kruyer, A., Samaha, A., & Heinz, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00314 · Cited by 47
Challenges of Delirium Management in Patients with Traumatic Brain Injury: From Pathophysiology to Clinical Practice
Roberson, S. W., Patel, M. B., Dąbrowski, W., Ely, E. W., Pakulski, C., & Kotfis, K. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210119153839 · Cited by 50
Pediatric Bipolar Disorder: Emerging Diagnostic and Treatment Approaches
Kowatch, R. A., & DelBello, M. P. (2006) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.08.013 · Cited by 45
Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain
Terry, A. V., Gearhart, D. A., Mahadik, S. P., Warsi, S., & Waller, J. L. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.03.011 · Cited by 46
Psychotropic drug therapy in patients in the intensive care unit - usage, adverse effects and drug interactions: a review
Shafiekhani, M., Mirjalili, M., & Vazin, A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s176079 · Cited by 44
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders
Lafuente, A., Bernardo, M., Mas, S., Crescenti, A., Aparici, M., Gassó, P., Deulofeu, R., Mané, A., Catalán, R., & Carné, X. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.08.002 · Cited by 45
Antidepressant and Antipsychotic Drugs
Krystal, A. D. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.010 · Cited by 49
SNP-based analysis of neuroactive ligand–receptor interaction pathways implicates PGE2 as a novel mediator of antipsychotic treatment response: Data from the CATIE study
Adkins, D. E., Khachane, A. N., McClay, J. L., Åberg, K. A., Bukszár, J., Sullivan, P. F., & van den Oord, E. J. C. G. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.002 · Cited by 45
Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Gαi1- and neutral antagonism for Gαq/11-proteins in human brain cortex
Arrate, I. M., Dı́ez-Alarcia, R., Horrillo, I., & Meana, J. J. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.05.004 · Cited by 45
Design, Optimization, and Biological Evaluation of Novel Keto-Benzimidazoles as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A)
Hu, E., Kunz, R. K., Chen, N., Rumfelt, S., Siegmund, A., Andrews, K. L., Chmait, S., Zhao, S., Davis, C. D., Chen, H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401234w · Cited by 44
The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol
Živković, M., Mihaljević-Peleš, A., Božina, N., Šagud, M., Perković, M. N., Vuksan‐Ćusa, B., & Mück‐Šeler, D. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829abec9 · Cited by 44
Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138
Millan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 44
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis
Sacchetti, E., Magri, C., Minelli, A., Valsecchi, P., Traversa, M., Calza, S., Vita, A., & Gennarelli, M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.90 · Cited by 44
Time-Dependent Effects of Haloperidol and Ziprasidone on Nerve Growth Factor, Cholinergic Neurons, and Spatial Learning in Rats
Terry, A. V., Parikh, V., Gearhart, D. A., Pillai, A., Hohnadel, E. J., Warner, S., Nasrallah, H. A., & Mahadik, S. P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099218 · Cited by 44
Dopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum
Fuxé, K., Borroto‐Escuela, D. O., Tarakanov, A. O., Romero‐Fernandez, W., Ferraro, L., Tanganelli, S., Pérez‐Alea, M., Palma, M. D., & Agnati, L. F. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00005-2 · Cited by 43
Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning
Li, M., Sun, T., Zhang, C., & Hu, G. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1925-5 · Cited by 43
Biomarkers for Psychiatric Disorders
Turck, C. W. (2009) · Springer eBooks · doi:10.1007/978-0-387-79251-4 · Cited by 42
Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks
Citrome, L., & Kantrowitz, J. T. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1079 · Cited by 43
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice
Thomsen, M., Wörtwein, G., Fink‐Jensen, A., Woldbye, D. P. D., Wess, J., & Caine, S. B. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0682-y · Cited by 43
Current schizophrenia drugs: efficacy and side effects
Krebs, M., Leopold, K., Hinzpeter, A., & Schaefer, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1005 · Cited by 43
Fine-Tuning of Awake Prefrontal Cortex Neurons by Clozapine: Comparison With Haloperidol and N-Desmethylclozapine
Homayoun, H., & Moghaddam, B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.016 · Cited by 42
5-HT2C Agonists as Therapeutics for the Treatment of Schizophrenia
Rosenzweig-Lipson, S. J., Comery, T. A., Marquis, K. L., Groß, J., & Dunlop, J. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_6 · Cited by 42
Antipsychotic Drugs Activate the C. elegans Akt Pathway via the DAF-2 Insulin/IGF-1 Receptor
Weeks, K. R., Dwyer, D. S., & Aamodt, E. J. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100010p · Cited by 42
In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic
Kaczor, A. A., Targowska‐Duda, K. M., Budzyńska, B., Biała, G., Silva, A., & Castro, M. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.03.003 · Cited by 42
Analysis of Adverse Drug Reactions of Atypical Antipsychotic Drugs in Psychiatry OPD
Piparva, K. G., Buch, J. G., & Chandrani, K. V. (2011) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.92067 · Cited by 42
Phosphodiesterase 10A in Schizophrenia: A PET Study Using [11C]IMA107
Marques, T. R., Natesan, S., Niccolini, F., Politis, M., Gunn, R. N., Searle, G. E., Howes, O. D., Rabiner, E. A., & Kapur, S. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040518 · Cited by 42
Antipsychotic clozapine inhibits the function of α7-nicotinic acetylcholine receptors
Singhal, S. K., Zhang, L., Morales, M., & Öz, M. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.023 · Cited by 42
New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways
Lodge, D. J., & Perez, S. M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s42708 · Cited by 42
Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders
Wesseling, H., Guest, P. C., Lee, C., Wong, E. H. F., Rahmoune, H., & Bahn, S. (2014) · Molecular Autism · doi:10.1186/2040-2392-5-38 · Cited by 42
5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia
Haleem, D. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000123 · Cited by 41
The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies
Kraeuter, A.-K., Phillips, R., & Sarnyai, Z. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00799 · Cited by 43
Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia
Fuxé, K., Marcellino, D. J., Woods, A. S., Leo, G., Antonelli, T., Ferraro, L., Tanganelli, S., & Agnati, L. F. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0174-9 · Cited by 40
Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia
Hänninen, K., Katila, H., Kampman, O., Anttila, S. A. K., Illi, A., Rontu, R., Mattila, K. M., Hietala, J. A., Hurme, M., Leinonen, E. V. J., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.041 · Cited by 41
Glutamate, obsessive–compulsive disorder, schizophrenia, and the stability of cortical attractor neuronal networks
Rolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats
Sun, T., He, W., Hu, G., & Li, M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.02.005 · Cited by 42
Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout Mice
Kurita, M., Moreno, J. L., Holloway, T. D., Kozlenkov, A., Mocci, G., García‐Bea, A., Hanks, J. B., Neve, R. L., Nestler, E. J., Russo, S. J., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084582 · Cited by 39
Clozapine Treatment Causes Oxidation of Proteins Involved in Energy Metabolism in Lymphoblastoid Cells: A Possible Mechanism for Antipsychotic- Induced Metabolic Alterations
Baig, M. R., Navaira, E., Escamilla, M., Raventós, H., & Walss‐Bass, C. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000388627.36781.6a · Cited by 41
NC-1900, an arginine–vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: Therapeutic implications for schizophrenia
Matsuoka, T., Sumiyoshi, T., Tanaka, K., Tsunoda, M., Uehara, T., Itoh, H., & Kurachi, M. (2005) · Brain Research · doi:10.1016/j.brainres.2005.06.035 · Cited by 40
Ketamine-induced changes in connectivity of functional brain networks in awake female nonhuman primates: a translational functional imaging model
Gopinath, K., Maltbie, E. A., Urushino, N., Kempf, D., & Howell, L. L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4401-z · Cited by 40
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 48
Antipsychotic drugs on maternal behavior in rats
Li, M. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000168 · Cited by 38
Quetiapine, Olanzapine and Haloperidol Affect Human Plasma Lipid Peroxidation in vitro
Dietrich‐Muszalska, A., Kontek, B., & Rabe‐Jabłońska, J. (2011) · Neuropsychobiology · doi:10.1159/000321623 · Cited by 38
Bioanalytical methods for the determination of antipsychotic drugs
Zhang, G., Terry, A. V., & Bartlett, M. G. (2008) · Biomedical Chromatography · doi:10.1002/bmc.997 · Cited by 38
The receptor mechanisms underlying the disruptive effects of haloperidol and clozapine on rat maternal behavior: A double dissociation between dopamine D2 and 5-HT2A/2C receptors
Zhao, C., & Li, M. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.06.005 · Cited by 38
Paliperidone Extended‐Release for the Treatment of Schizophrenia
Marino, J., & Caballero, J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.10.1283 · Cited by 38
Pharmacogenetic considerations in the treatment of psychiatric disorders
Lohoff, F. W., & Ferraro, T. N. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903508762 · Cited by 38
Discovery of Clinical Candidate 1-(4-(3-(4-(1H-Benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), A Potent, Selective, and Efficacious Inhibitor of Phosphodiesterase 10A (PDE10A)
Hu, E., Chen, N., Bourbeau, M. P., Harrington, P. E., Biswas, K., Kunz, R. K., Andrews, K. L., Chmait, S., Zhao, X., Davis, C. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500713j · Cited by 38
Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs
Goodlet, K. J., Zmarlicka, M. T., & Peckham, A. M. (2018) · CNS Spectrums · doi:10.1017/s109285291800113x · Cited by 40
Are Circadian Disturbances a Core Pathophysiological Component of Schizophrenia?
Delorme, T. C., Srivastava, L. K., & Cermakian, N. (2020) · Journal of Biological Rhythms · doi:10.1177/0748730420929448 · Cited by 44
Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum
Dlaboga, D., HajjHussein, H., & O’Donnell, J. M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.002 · Cited by 38
Calibration and cross-validation of MCCB and CogState in schizophrenia
Lees, J., Applegate, E., Emsley, R., Lewis, S. W., Michalopoulou, P. G., Collier, T., Lopez‐Lopez, C., Kapur, S., Pandina, G., & Drake, R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3960-8 · Cited by 37
Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules
Mouri, A., Nagai, T., Ibi, D., & Yamada, K. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.025 · Cited by 38
Aberrant neural synchrony in the maternal immune activation model: using translatable measures to explore targeted interventions
Dickerson, D. D., & Bilkey, D. K. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00217 · Cited by 40
Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents
Mogwitz, S., Buse, J., Wolff, N., & Roessner, V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00460 · Cited by 37
Determination of antipsychotic drugs in oral fluid using dried saliva spots by gas chromatography-tandem mass spectrometry
Caramelo, D., Rosado, T., de Oliveira, V. A. P., Rodilla, J. M., Rocha, P., Barroso, M., & Gallardo, E. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02005-8 · Cited by 37
A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia
Girgis, R. R., Forbes, A., Abi‐Dargham, A., & Slifstein, M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0590-6 · Cited by 37

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks